Nicotine Sublingual Therapy for Ischemia Reperfusion Trauma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute renal and pulmonary trauma caused by ischemia/reperfussion lack effective agents that can simultaneously inhibit both local and distant organ damage, leading to high morbidity and mortality, with existing therapies being limited and not addressing the underlying inflammatory mechanisms effectively.
Innovation Solution
Administration of α-MSH hormone, which is a potent anti-inflammatory peptide, to inhibit inflammatory mediators and pathways, thereby reducing tissue damage and improving outcomes in ischemia/reperfussion models, and using nicotine sublingually to induce tonic release of α-MSH from melanotrophs in the pars intermedia of the hypophysis, influencing the hypothalamus to suppress dopamine secretion and enhance α-MSH release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for ischemia/reperfussion trauma, then treatment is provided, but they fail to simultaneously inhibit both local and distant organ damage
Solution Approach 1:
The patent applies universality by using a single therapeutic agent (α-MSH or nicotine) that simultaneously addresses multiple organ damage. The invention demonstrates that α-MSH treatment can inhibit both local renal damage and distant pulmonary trauma caused by ischemia/reperfussion, making the treatment multi-functional rather than organ-specific.
Solution Approach 2:
The patent uses nicotine as an intermediary substance that indirectly activates the α-MSH system. Instead of directly administering α-MSH, the invention employs nicotine to stimulate endogenous α-MSH release, creating a mediator-based treatment approach that leverages the body's own protective mechanisms.
2Object-affected harmful factors
If no effective anti-inflammatory agent is used, then treatment is simple, but inflammatory pathways cause extensive tissue damage
Solution Approach 1:
The patent applies self-service by stimulating the body's endogenous protective mechanisms. Instead of providing exogenous anti-inflammatory agents, the invention uses nicotine to trigger the release of endogenous α-MSH, allowing the body to fight its own inflammation rather than relying on external substances.
Solution Approach 2:
The patent converts the harmful inflammatory response into a beneficial protective mechanism by activating the α-MSH system. The same inflammatory pathways that cause damage are counteracted by the body's own anti-inflammatory peptides, turning the harmful process into an opportunity for endogenous protection.
3Reliability
If mortality from multiple organ failure is high, then prognosis is poor, but new therapeutic strategies are needed
Solution Approach 1:
The patent applies preliminary action by administering treatment before multiple organ failure develops. The invention focuses on early intervention during the ischemia/reperfussion event to prevent the cascade of inflammatory damage that leads to organ failure, rather than treating after damage has occurred.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
α-MSH significantly reduces renal and pulmonary trauma by inhibiting inflammatory pathways, including TNF-α and ICAM-1, and nicotine's sublingual administration promotes sustained α-MSH release, offering a therapeutic effect in conditions like hyphema by reducing inflammation and promoting tissue protection.
Implementation Method 1
Administration of nicotine, analogues, precursors, or derivatives by the sublingual pathway
Implementation Method 2
the α-MSH releasing induced by melanotrophs from pars intermedia of the hypophysis
Implementation Method 3
The anti-inflammatory effects are mainly through the antagonism of proinflammatory mediators including α-Tumor Necrosis Factor, Interleukina 6 and nitric oxide (NO)
Implementation Method 4
acute renal and pulmonary trauma caused by ischemia/reperfussion
Implementation Method 5
severe trauma, burns, haemorrhages, sepsis, shock, or severe local tissular trauma, can iniciate a systemic inflammatory response
Data Source
AI summary
The invention relates to nicotine, analogues thereof, precursors thereof, or its derivatives in effective dose form and adequate pharmacophore for the treatment of post traumatic bleeding in humans and/or animals, in particular in mammalians.